Stay updated with breaking news from Fred Ors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr. Graff will lead IMV’s research to continue the expansion of DPX- based immuno-oncology pipeline and the development of a comprehensive translational strategy to optimize clinical success Industry veteran Stanley Frankel, M.D. to advise on clinical development DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--$IMV #Delive...
Dr. Graff will lead IMV's research to continue the expansion of DPX- based immuno-oncology pipeline and the development of a comprehensive translational strategy to optimize... | June 9, 2021
Operator Good morning, and thank you for standing by. Welcome to the IMV Inc. first-quarter 2021 conference call. [Operator instructions] I would now like to hand the conference over to Pierre Labbé, chief financial officer. Thank you. Please go ahead. Pierre Labbe -- Chief Financial Officer Thank you, Takke. Good morning, everyone. My name is Pierre Labbé, CFO at IMV, and I'm pleased to welcome you to our clinical and operational update and first-quarter financial results conference call. I'm joined today by Fred Ors, our chief executive officer; and Andrew Hall, our chief business office...
Press release content from Business Wire. The AP news staff was not involved in its creation. IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline May 12, 2021 GMT DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--May 12, 2021-- IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the first quarter ended March 31, 2021. “We remain focused on our commitment to provide effective and well...
Press release content from Business Wire. The AP news staff was not involved in its creation. IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results March 17, 2021 GMT DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--Mar 17, 2021-- IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and year ended December 31, 2020. “Notwithstanding the challenges everyone faced in 2020, IMV’s commitment ...